Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193256 · ClinicalTrials.gov registry record · Early Phase 1
Varenicline + Prazosin for Heavy Drinking Smokers
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT02193256 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT02193256, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effect of varenicline and prazosin on smoking, drinking, and sleep among cigarette smokers who report heavy alcohol use. Varenicline is an FDA approved smoking cessation medication. Some smokers report sleep problems when taking varenicline. This study will test whether using prazosin, which is an FDA-approved blood pressure medication, in combination with varenicline reduces sleep problems that can be associated with using varenicline for smoking cessation. In addition, the study will examine the combined effects of these medications on smoking and drinking. Hypothesis: Varenicline plus prazosin will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than varenicline alone prior to the 3-day practice quit attempt. Hypothesis: Varenicline plus prazosin will result in lower rates of vivid dreams and insomnia symptoms/sleep discontinuity than varenicline alone during the 3-day practice quit attempt.
Interventions
- DRUG Placebo
- DRUG Varenicline
- DRUG Prazosin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193256
The ClinicalTrials.gov registry entry for NCT02193256 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02193256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02193256 about?
NCT02193256 is a clinical study titled "Varenicline + Prazosin for Heavy Drinking Smokers". The purpose of this study is to examine the effect of varenicline and prazosin on smoking, drinking, and sleep among cigarette smokers who report heavy alcohol use. Varenicline is an FDA approved smoking cessation medication. Some smokers report sleep problems when taking varenicline. This study wil...
What is the current status of trial NCT02193256?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2014-07. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02193256?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT02193256?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.